Dutch ingredients Firm Vivici Partners With Ginkgo Bioworks For Alternative Protein Development
Portfolio Pulse from Shivani Kumaresan
Vivici BV, a Dutch B2B ingredients company, has partnered with Ginkgo Bioworks Holdings Inc (NYSE:DNA) to develop and commercialize alternative dairy proteins using precision fermentation. Ginkgo will provide optimized strains for dairy protein production, which Vivici will use to expand their protein range for specialized nutrition companies. Ginkgo's Protein Production Services and AI platform will be utilized in the process. DNA shares saw a slight decrease of 0.68% to $1.45 in premarket trading.

November 27, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ginkgo Bioworks Holdings Inc is partnering with Vivici BV to develop alternative dairy proteins. The collaboration leverages Ginkgo's strain optimization and AI platform, aiming to enhance Vivici's product offerings in specialized nutrition.
The partnership with Vivici BV could be positive for Ginkgo Bioworks as it expands its application of precision fermentation in the alternative protein market. However, the slight premarket dip in DNA shares suggests a neutral to mildly negative short-term investor reaction, possibly due to market conditions or the early stage of the partnership. The impact on the stock price may be limited in the short term until more tangible results from the partnership are evident.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80